Contact Us Site Map Directions Join our Mailing List
 
Washington Technology Center Funding & Services Microfabrication Lab Industries Initiative News Forum
News Forum

IsoRay announces a distribution agreement in Canada and another with GE subsidiary Oncura

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced two new distribution agreements. Inter V Medical of Montreal, Quebec, Canada will have exclusive rights to sell Cesium-131 Brachytherapy seeds in Canada. GE Subsidary, Oncura will distribute the I-125 brachytherapy seed, OncoSeedâ„¢.

In a press release, Dwight Babcock, Chairman and CEO stated, "By adding I-125 seeds to our prostate product offering we can now be a full service provider to our customers. OncoSeed brings with it a substantial and well documented track record of efficacy. While we believe that Cesium-131 adds an important new dimension to brachytherapy for a variety of anatomic sites including prostate, we see strategic value in supporting our customers that have not yet converted all their practice to Cesium-131."

Related external links (will open a new window):

  • IsoRay, Inc. Announces Iodine Distribution Agreement with GE Subsidary, Oncura
    IsoRay - Richland, Wash. - December 3, 2009
  • IsoRay, Inc. Announces Distribution Agreement in Canada
    IsoRay - Richland, Wash. - November 18, 2009

    Related WTC links:

  • IsoRay is a WTC client
  • IsoRay announces world's first Cesium-131 lung implants
    Posted 11/05/2009
  • IsoRay announces first head and neck cancer treated with Cesium-131
    Posted 8/07/2009
  • IsoRay receives approval to market cancer therapy in Canada
    Posted 5/12/2009
  • IsoRay signs distribution agreement for prostate brachytherapy product
    Posted 2/19/2009

    - end of post -

    Labels: , , , , ,

  • >> Start a discussion on this topic

    0 Comments:

    Post a Comment

    Your comments are encouraged. By posting a comment, you grant WTC the right to use the content for promotional or marketing purposes. We review comments during business hours before posting to our site.

    << Back to News Forum Home